MyMD Pharmaceuticals, Inc. Common Stock (DE)
Compare this stock
MYMD Stock Report Card
$
18%
Performance
Score:
10/100
MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
25/100
MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
Profit
Score:
10/100
Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
40/100
MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.
MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary
Nasdaq / MYMD
Healthcare
Biotechnology
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
MYMD scored poorly on our reportcard. Here are some similar companies and how they performed.
